Aya Ugamura, Po‐sung Chu, Nobuhiro Nakamoto, Nobuhito Taniki, Keisuke Ojiro, Taizo Hibi, Masahiro Shinoda, Hideaki Obara, Yohei Masugi, Akihiro Yamaguchi, Shunsuke Shiba, Rei Morikawa, Shingo Usui, Hirotoshi Ebinuma, Yuko Kitagawa, Hidetsugu Saito, Takanori Kanai – 21 September 2018 – A prognostic system for acute liver failure (ALF) with a higher predictive value is urgently needed. The role of extracellular matrix (ECM) remodeling in ALF has not been fully elucidated.

Virginia Hernández‐Gea, Juan Carlos Garcia‐Pagan – 21 September 2018

Patrick H. Y. Chung, Kelvin K. C. Ng, Tiffany C. L. Wong, Sui Ling Sin, Chung Mau Lo – 21 September 2018

Charlotte E. Costentin, Yanik J. Bababekov, Andrew X. Zhu, Heidi Yeh – 19 September 2018 – Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) because it removes tumor as well as the underlying cirrhotic liver. Because of a global organ shortage, LT for patients with HCC is limited to patients with expected survival comparable to that of nonmalignant indications. Therefore, identifying patients with lower rates of HCC recurrence and higher rates of survival is critical.

Jeannette D. Widmer, Andrea Schlegel, Mohamed Ghazaly, Brian Richie Davidson, Charles Imber, Dinesh Sharma, Massimo Malago, Joerg‐Matthias Pollok – 19 September 2018 – The cava‐preserving piggyback (PB) technique requires only partial cava clamping during the anhepatic phase in liver transplantation (LT) and, therefore, maintains venous return and may hemodynamically stabilize the recipient. Hence, it is an ongoing debate whether PB implantation is more protective from acute kidney injury (AKI) after LT when compared with a classic cava replacement (CR) technique.

Britt A. Blokker, Monica Maijo, Marta Echeandia, Mikel Galduroz, Angela M. Patterson, Anna Ten, Mark Philo, Rebecca Schungel, Virginia Gutierrez‐de Juan, Emina Halilbasic, Claudia Fuchs, Gwenaelle Le Gall, Malgorzata Milkiewicz, Piotr Milkiewicz, Jesus M. Banales, Simon M. Rushbrook, José M. Mato, Michael Trauner, Michael Müller, María Luz Martínez‐Chantar, Marta Varela‐Rey, Naiara Beraza – 19 September 2018 – Cholestasis comprises aetiologically heterogeneous conditions characterized by accumulation of bile acids in the liver that actively contribute to liver damage.

Douglas B. Mogul, Xun Luo, Jacqueline Garonzik‐Wang, Mary G. Bowring, Allan B. Massie, Kathleen B. Schwarz, Andrew M. Cameron, John F. P. Bridges, Dorry L. Segev – 19 September 2018 – The increased use of split‐liver transplantation (SLT) represents a strategy to increase the supply of organs. Although outcomes after SLT and whole liver transplantation (WLT) are similar on average among pediatric recipients, we hypothesized that the relationship between graft type and outcomes may vary depending on patient, donor, and surgical characteristics.

Peter Ferenci, Wolfgang Stremmel, Anna Członkowska, Ferenc Szalay, André Viveiros, Albert Friedrich Stättermayer, Radan Bruha, Roderick Houwen, Tudor Lucian Pop, Rudolf Stauber, Michael Gschwantler, Jan Pfeiffenberger, Cihan Yurdaydin, Elmar Aigner, Petra Steindl‐Munda, Hans‐Peter Dienes, Heinz Zoller, Karl Heinz Weiss – 19 September 2018 – Wilson disease (WD) is an inherited disorder of hepatic copper metabolism with considerable variation in clinical presentations, the most common ones being liver disease and neuropsychiatric disturbances.

Janghyun Kim, Bora Lee, Dae‐Hwan Kim, Jae Gwang Yeon, Jeongkyung Lee, Younjung Park, Yuna Lee, Soo‐Kyung Lee, Seunghee Lee, Jae W. Lee – 19 September 2018 – Regulation of the protein stability of epigenetic regulators remains ill‐defined despite its potential applicability in epigenetic therapies. The histone H3‐lysine 4‐methyltransferase MLL4 is an epigenetic transcriptional coactivator that directs overnutrition‐induced obesity and fatty liver formation, and Mll4+/‐ mice are resistant to both.

Charlotte E. Costentin, Yanik J. Bababekov, Andrew X. Zhu, Heidi Yeh – 19 September 2018 – Liver transplantation (LT) is considered the optimal treatment for hepatocellular carcinoma (HCC) because it removes tumor as well as the underlying cirrhotic liver. Because of a global organ shortage, LT for patients with HCC is limited to patients with expected survival comparable to that of nonmalignant indications. Therefore, identifying patients with lower rates of HCC recurrence and higher rates of survival is critical.